Sanofi has finalized the acquisition of Inhibrx, Inc., incorporating the promising rare disease treatment SAR447537 into its portfolio. This acquisition underscores Sanofi’s commitment to advancing novel medicines. SAR447537, a human recombinant protein, could offer a more convenient dosing schedule for patients with alpha-1 antitrypsin deficiency (AATD), a condition that primarily affects lung function. The acquisition was supported by Inhibrx shareholders and valued at approximately $1.7 billion. The deal included a spin-off of Inhibrx Biosciences, which will retain assets not related to SAR447537. Post-acquisition, Sanofi utilized Lazard and Weil, Gotshal & Manges LLP as advisors, while Inhibrx was supported by Centerview Partners LLC and Paul, Weiss, Rifkind, Wharton & Garrison LLP. Inhibrx Biosciences will continue trading on NASDAQ under new tickers INXB and INBX.

Pharmaceuticals, Biotechnology,United States, France